



#3

PATENT  
ATTORNEY DOCKET NO.: JHU1630-1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Sukumar et al. Art Unit: 1655  
Application No.: 10/059,579 Examiner: Unknown  
Filed: January 28, 2002  
Title: ABERRANTLY METHYLATED GENES AS MARKERS OF BREAST  
MALIGNANCY

**BOX MISSING PARTS**

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.


CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <b>January 28, 2003</b> , in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.	
<b>Cecilia Tobin</b> (Name of Person Mailing Paper)	
<i>Cecilia Tobin</i> (Signature)	<b>January 28, 2003</b> (Date)

Applicants: Sukumar et al.  
Application No.: 10/059,579  
Filed: January 28, 2002  
Page 2


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the receipt of a first office action on the merits of the above-captioned application. However, if any fee is required, authorization is hereby given charge any fees associated with the filings submitted herewith, or credit any overpayment to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: January 28, 2003

  
June M. Learn, J.D.  
Registration No. 31,238  
Telephone: (858) 677-1416  
Facsimile: (858) 677-1465

**USPTO CUSTOMER NUMBER 28213**  
GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No. (Optional)</b> JHU1630-1	<b>Application No.:</b> 10/059,579
	<b>Applicants:</b> Sukumar et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 28, 2003	<b>Group Art Unit:</b> 1655

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	5,786,146	07/28/98	Herman et al.			
	AB	6,017,704	01/25/00	Herman et al.			
	AC	6,200,756 B1	03/13/01	Herman et al.			

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
		NONE					


### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AD 1	Baylin and Herman, "DNA hypermethylation in tumorigenesis," <i>TIG</i> <b>16</b> (4):168-174 (2000)
	AE 2	Ferguson, et al., "High frequency of hypermethylation at the 14-3-3 $\sigma$ locus leads to gene silencing in breast cancer," <i>PNAS</i> <b>97</b> (11):6049-6054 (2000)
	AF 3	Ferguson, et al., "Demethylation of the Estrogen Receptor Gene in Estrogen Receptor-negative Breast Cancer Cells Can Reactivate Estrogen Receptor Gene Expression," <i>Cancer Research</i> <b>55</b> :2279-2283 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No. (Optional)</b> JHU1630-1	<b>Application No.:</b> 10/059,579
	<b>Applicants:</b> Sukumar et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> January 28, 2003	<b>Group Art Unit:</b> 1655

	AG ↓	Nass, et al., "Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5' CpG Islands Increases with Malignant Progression in Human Breast Cancer," <i>Cancer Research</i> <b>60</b> :4346-4348 (2000)
	AH ↓	Ottaviano, et al., "Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cell," <i>Cancer Research</i> <b>54</b> :2552-2555 (1994)
	AI ↓	Raman, et al., "Compromised HOXA5 function can limit p53 expression in human breast tumours," <i>Nature</i> <b>405</b> :974-976 (2000)
	AJ ↓	Raman, et al., "HOXA5 Regulates Expression of the Progesterone Receptor," <i>The Journal of Biological Chemistry</i> <b>275 (34)</b> :26551-26555 (2000)
	AK ↓	Sirchia, et al., "Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor $\beta$ 2 promoter in breast cancer cells," <i>Oncogene</i> <b>19</b> :1556-1563 (2000)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449